Sector News

Gamida Cell appoints Julian Adams Chairman and CEO

November 20, 2017
Life sciences

Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Julian Adams, Ph.D., as chairman and chief executive officer.

Dr. Adams brings more than 30 years of drug discovery and development experience to his new role as CEO of Gamida Cell. He succeeds Yael Margolin, Ph.D., who has led the company from preclinical development to a company in phase 3 development. Dr. Margolin will remain president of Gamida Cell, continuing to lead the team in Jerusalem.

“Gamida Cell’s proprietary NAM technology platform has unprecedented potential to create curative cellular and immune therapeutics for a diverse population of patients in need,” said Dr. Adams. “I am excited to be joining such a talented team as we begin to prepare for the commercialization of our lead program, NiCord, which is currently in phase 3 clinical testing. I would like to thank Yael for her dedication throughout her time as CEO, and look forward to partnering with her to realize the potential of this promising pipeline for patients with cancer and rare genetic diseases.”

Prior to this appointment, Dr. Adams served as president and chief scientific officer at Clal Biotechnology Industries (CBI), where he oversaw the Boston office, evaluating investment opportunities and supporting portfolio companies, including Gamida Cell. Before joining CBI, he served as the president of research and development at Infinity Pharmaceuticals, where he built and led the company’s R&D efforts. Dr. Adams also served as senior vice president of drug discovery and development at Millennium Pharmaceuticals, where he played a key role in the discovery of Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer, multiple myeloma. Earlier in his career, he was credited with discovering Viramune® (nevirapine) for HIV at Boehringer Ingelheim. He has also held senior leadership roles in research and development at LeukoSite and ProScript.

Dr. Adams has won several awards for his drug development efforts throughout his career, holds more than 40 patents from the United States Patent and Trademark Office (USPTO) and has authored more than 100 papers and book chapters in peer-reviewed journals. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology. He also earned a Doctor of Science, honoris causa, from McGill University in 2012.

“Julian is one of the most respected leaders in the biotechnology industry and has successfully led the global development and registration of multiple clinical programs,” said Dr. Margolin. “This is a dynamic time at Gamida Cell and as we advance the pipeline including our lead candidate, NiCord, we are excited to have Julian join us and support our objectives of expanding Gamida Cell’s global presence in the U.S. market.”

Source: Gamida Cell

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.